Rhabdomyolysis-induced acute kidney injury in a cancer patient exposed to denosumab and abiraterone: a case report by Javier A. Neyra et al.
CASE REPORT Open Access
Rhabdomyolysis-induced acute kidney
injury in a cancer patient exposed to
denosumab and abiraterone: a case report
Javier A. Neyra1,2*, Natalia A. Rocha1, Rhea Bhargava4, Omkar U. Vaidya4,5, Allen R. Hendricks3 and Aylin R. Rodan1,2
Abstract
Background: Denosumab and abiraterone were approved by the United States Food and Drug Administration in
2011 for the treatment of metastatic castration-resistant prostate cancer. Neither denosumab nor abiraterone is
known to cause rhabdomyolysis.
Case presentation: A 76-year-old Caucasian man with metastatic prostate cancer presented with non-oliguric
severe acute kidney injury (AKI) 3 weeks after receiving simultaneous therapy with denosumab and abiraterone.
The patient had been on statin therapy for more than 1 year with no recent dose adjustments. His physical exam
was unremarkable. Blood work on admission revealed hyperkalemia, mild metabolic acidosis, hypocalcemia, and
elevated creatine kinase (CK) at 44,476 IU/L. Kidney biopsy confirmed the diagnosis of rhabdomyolysis-induced
AKI. The patient responded well to intravenous isotonic fluids and discontinuation of denosumab, abiraterone,
and rosuvastatin, with normalization of CK and recovery of kidney function.
Conclusion: We report the first case of biopsy-proven rhabdomyolysis-induced AKI in a cancer patient acutely
exposed to denosumab and abiraterone. Whether one of these drugs individually, or the combination, was the
bona fide culprit of muscle breakdown is unknown. Nonetheless, our report is hypothesis-generating for further
investigations on the effect of these drugs on muscle cells.
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Background
Rhabdomyolysis is characterized by muscle breakdown
leading to leakage of sarcoplasmic proteins, electrolytes,
and myoglobin into the circulation [1]. Several provok-
ing factors (Table 1) can trigger muscle cell death
through direct sarcolemmic injury or depletion of ad-
enosine triphosphate within the myocyte [2]. The final
common pathway is an increase in intracellular calcium
and consequent protease activation, mitochondrial dys-
function, and production of reactive oxygen species
that precipitate muscle cell death [3, 4].
One of the common complications of rhabdomyolysis
is acute kidney injury (AKI). In the US, rhabdomyolysis
is the cause of up to 10 % of all cases of AKI [5] and the
mortality rate associated with rhabdomyolysis-induced
AKI can be as high as 30 %, depending on subjects’ co-
morbidities [6]. The occurrence of AKI in rhabdomyolysis
is likely from a combination of risk factors that include
volume depletion, intrarenal vasoconstriction, direct and
ischemic proximal tubular injury (myoglobin-driven), and
tubular obstruction [7]. The latter mainly occurs in the
distal tubules where myoglobin interacts with Tamm–
Horsfall protein, particularly in acidic urine [1, 7].
Pharmacologic agents constitute important causes of
non-exertional and non-traumatic rhabdomyolysis [6, 8].
Several drugs such as antipsychotics, statins, and select-
ive serotonin reuptake inhibitors have been identified as
common culprits of rhabdomyolysis [6, 9], particularly
in combination with other patient-specific risk factors.
In 2011, denosumab and abiraterone were approved
by the United States Food and Drug Administration for
the treatment of metastatic castration-resistant prostate
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cancer. We present the case of a 76-year-old Caucasian
man with a history of metastatic prostate cancer who de-
veloped rhabdomyolysis-induced AKI after acute expos-
ure to denosumab and abiraterone.
Case presentation
A 76-year-old Caucasian man with a history of type 2
diabetes, chronic kidney disease (CKD) stage 3A, essen-
tial hypertension, hypothyroidism, antiphospholipid anti-
body syndrome, prior cerebellar strokes, and prostate
cancer (Gleason 10) with widespread metastasis to the
bone presented with non-oliguric severe AKI 3 weeks
after receiving simultaneous therapy with denosumab
(120 mg subcutaneous injection once) and abiraterone
(1 g per day orally). The patient had failed prior antineo-
plastic therapy with leuprolide acetate, bicalutamide, and
nilutamide. On admission, his serum creatinine (SCr)
was elevated at 5.7 mg/dL from a baseline of 1.2 mg/dL
(Fig. 1). His active outpatient medications consisted of
rosuvastatin (40 mg daily), benazepril, metoprolol tar-
trate, metformin, warfarin, low-dose prednisone (started
concomitantly with abiraterone), and levothyroxine. The
patient had been on statin therapy for more than 1
year and the dose had not been recently modified. The
patient denied prior episodes of myopathies, rhabdo-
myolysis, or AKI. His physical exam was unremark-
able. Further blood work showed hyperkalemia, mild
metabolic acidosis, hypocalcemia, mild transaminemia
(predominantly AST), and creatine kinase (CK) of
44,476 IU/L (Table 2). Urine studies revealed dipstick
proteinuria (100 mg/dL), large dipstick blood, only a
few normomorphic erythrocytes, and negative culture.
All serologic work-up (ANA, PR3- and MPO-ANCA,
anti-GBM antibodies, ENA panel, C3, C4, RF) and viral
studies (HBV, HCV, CMV, EBV, Influenza A/B, Parainflu-
enza, Adenovirus, RSV) were negative or normal. Thyroid
function tests were normal. Kidney sonogram and Dop-
pler studies were negative for hydronephrosis and renal
vein thrombosis, respectively. On admission, abirater-
one therapy was discontinued and no further doses of
denosumab were administered. Subsequently, the pa-
tient underwent kidney biopsy that was consistent with
severe acute tubular injury with presence of myoglobin
casts, confirming the diagnosis of rhabdomyolysis-induced
AKI (Figs. 2 and 3). The patient responded well to intra-
venous isotonic fluids and discontinuation of denosumab,
abiraterone, and rosuvastatin. CK levels normalized by
day 25 of hospitalization and the SCr at the time of
hospital discharge was 3.1 mg/dL (Fig. 1). After hospital
discharge, the patient resumed all prior medications,
including rosuvastatin, except for denosumab and abir-
aterone. His successive antineoplastic therapy consisted
of enzalutamide. Kidney function returned to baseline
12 months after discharge and he had no recurrent epi-
sodes of rhabdomyolysis.
Conclusion
We present a case of a patient with biopsy-proven AKI
caused by rhabdomyolysis 3 weeks after starting simul-
taneous treatment with denosumab and abiraterone. The
patient was also taking rosuvastatin, a drug known to
cause rhabdomyolysis [10]. However, his statin exposure
was chronic and without reported recent dose adjust-
ments. Most importantly, no other identifiable patient-
specific triggers for statin-related rhabdomyolysis (e.g.,
decompensated hypothyroidism, liver disease, strenuous
exercise, or recreational drug use) were identified upon
interrogation and examination. In addition, his statin
therapy was resumed after discharge with good tolerabil-
ity thereafter. Nonetheless, it is not known if drug-drug
interactions between the statin and denosumab or abira-
terone could augment the risk for rhabdomyolysis in
humans.
Denosumab is a human monoclonal antibody that
neutralizes the receptor activator of nuclear factor
kappa-B ligand (RANKL), inhibiting osteoclast-mediated
bone resorption [11]. It is used to prevent bone metasta-
sis and skeletal-related events in metastatic castration-
resistant prostate cancer [12, 13]. Some of the common
side effects of denosumab include back pain, cystitis,
and upper respiratory tract infections. Serious adverse
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events such as osteonecrosis of the jaw have been reported
in only 2 % of patients [14, 15]. Abiraterone is a CYP17A1
inhibitor that blocks the synthesis of androgens in prostate
tumor cells, the testes, and adrenal glands. Its side effects
are related to 17-alpha hydroxylase inhibition leading to a
decrease in cortisol production and consequent increase
in ACTH release, mineralocorticoid production, and
ensuing hypokalemia, which itself is a risk factor for
rhabdomyolysis [16, 17].
Prior to the development of abiraterone and its approval
as an adrenal androgen synthesis inhibitor, ketoconazole
was the only CYP17 inhibitor that was used to treat meta-
static castration-resistant prostate cancer [18]. However,
due to its actions on CYP3A and CYP24A1 and therefore
Fig. 1 Time-related serum creatinine (SCr) and creatine kinase (CK) changes in relation to denosumab and abiraterone exposure (D −21), hospital
admission (D1), and hospital discharge (D45). Gray arrow = denosumab 120 mg subcutaneous injection (single shot) and abiraterone started at
1 g orally per day. Black arrow = admission to the hospital, abiraterone stopped. Blue arrow = hospital discharge
Table 2 Urinary and blood biochemical profiles at baseline, time of hospital admission, and at the time of peak creatine kinase (CK)
Baseline (before admission) At the time of admission At the time of peak CK
Blood studies
Sodium, mmol/L 135[135–145] 137 134 (L)
Potassium, mmol/L 4.6 [3.6–5.0] 6.2 (H) 3.7
Phosphorus, mg/dL 2.9 [2.4–4.5] 2.4 2.5
Calcium, mg/dL 10 [8.4–10.2] 8.6 (L) 5.7 (L)
Ionized calcium, mg/dL – [4.5–5.3] – 3.4 (L)
Bicarbonate, mmol/L 29 [22–31] 21 (L) 13 (L)
Aspartate aminotransferase, U/L 29 [10–50] 354 (H) 1423 (H)
Alanine aminotransferase, U/L 19 [10–50] 125 (H) 330 (H)
Creatine kinase, IU/L – [39–308] 44,476 (H) 105,120 (H)
Lactate dehydrogenase, U/L – [135–225] 943 (H) 1135 (H)
Creatinine, mg/dL 1.2 [0.67–1.17] 5.7 (H) 5.2 (H)
eGFR, mL/min/1.73 m2a 59 10 (L) 11 (L)
Urine studies
pH – [5.0–6.0] 6 6
Dipstick blood – [negative] Large Large
Dipstick protein, mg/dL – [negative] 100 100
Specific gravity – [1.008–1.030] 1.018 1.013
Red blood cells/HPF – [0–3/HPF] 15 35
White blood cells/HPF – [0–5/HPF] <1 5
Squamous epithelial cells/HPF – [0–5/HPF] 10 <1
Leukocyte esterase – [negative] Negative Negative
[] = laboratory reference values; (H) = above laboratory reference value; (L) = below laboratory reference value; –= not measured; aeGFR = estimated glomerular
filtration rate by MDRD study equation
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the potential for drug-drug interactions, its use was lim-
ited to low-risk clinical scenarios [19]. A few cases of
rhabdomyolysis with the concomitant use of ketoconazole
and statin have been reported in the literature [20]. In this
context, the risk of rhabdomyolysis is thought to be
related to the inhibition of CYP3A by ketoconazole,
precipitating a significant increase in the plasma con-
centration of statin. In contrast, abiraterone is known
to act only on CYP17, with no apparent interference
with statin metabolism. According to the product in-
formation, abiraterone metabolites inhibit the hepatic
uptake transporter OATP1B1 in vitro, which may the-
oretically affect OATP1B1-mediated uptake of rosu-
vastatin, increase its levels, and therefore predispose
to toxicity [21–23]. To our knowledge, there are no
reported cases of rhabdomyolysis with either acute or
chronic exposure to abiraterone, alone or in conjunc-
tion with rosuvastatin.
Over the past few years, genetic experiments have un-
veiled numerous functions of the RANKL/RANK system
[11]. The best-known role of RANKL/RANK signaling is
in bone. Genetic ablation of RANKL or RANK in mice
results in a complete lack of osteoclasts, with conse-
quent osteopetrosis and defective tooth eruption [11].
Indeed, inhibition of RANKL/RANK function in osteo-
clast formation, survival, and function underlies the
therapeutic efficacy of denosumab in the treatment of
osteoporosis [24]. RANKL also participates in the com-
plex interplay of cancer cells with bone during bone me-
tastasis, by promoting osteoclast formation and thus
providing for establishment and growth of bone metas-
tases [25]. These actions of RANKL underlie the efficacy
of denosumab in ameliorating skeletal complications in
metastatic cancer [12, 13]. However, animal studies have
also revealed roles of this signaling pathway in extra-
skeletal tissues, such as in lymph node and immune
cell development, and in mammary gland development
and progestin-driven breast cancer [26]. Hypothalamic
RANKL/RANK signaling also plays a key role in thermo-
regulation and fever [27]. Thus, roles for RANKL/RANK
signaling have been found in bone, mammary tissue, the
immune system, and CNS, suggesting pleiotropic effects
on numerous cell and tissue types.
RANKL mRNA and protein are found in skeletal muscle
[28]. However, its function in skeletal muscle is currently
unknown, and awaits further studies with tissue-specific
knockouts. Therefore, the possible effects of denosumab
on skeletal muscle resulting in rhabdomyolysis remain
speculative at this time. Possible mechanisms include a
direct myopathic effect or alterations in calcium dynamics
in the muscle cell, leading to an increase in intracellular
calcium concentration and consequent rhabdomyolysis.
We report the first case of rhabdomyolysis leading to
severe AKI in association with acute exposure to deno-
sumab and abiraterone. From our case we are unable to
determine whether rhabdomyolysis was caused by one of
these two drugs, their mutual interaction, or their inter-
action with another commonly used drug, rosuvastatin.
Nonetheless, this case exposes the need to carefully
Fig. 3 Kidney biopsy light microscopy showing tubular casts staining
positively for myoglobin by immunohistochemistry (anti-myoglobin)
(yellow arrow), (X400)
Fig. 2 Kidney biopsy light microscopy. a Hematoxylin & eosin (X200) showing dark pink, filamentous tubular casts (yellow arrow); b) Jones’ silver
stain (X400) showing dark pink, coarsely granular and filamentous tubular casts (yellow arrow)
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monitor patients exposed to denosumab and abiraterone
to recognize potential severe adverse effects associated
with these novel therapies. In addition, our report is
hypothesis-generating to further investigate the effect of
these drugs on muscle cells. In conclusion, we recom-
mend monitoring for early signs of rhabdomyolysis in
high-risk patients exposed to either denosumab or abira-
terone, particularly if other identifiable risk factors are
present (Table 1), such as in the case of our patient (e.g.,
advanced age, CKD, type 2 diabetes, hypothyroidism, and
statin use).
Consent
The patient was deceased at the time of preparation of
this manuscript. Written informed consent was obtained
from his next-of-kin for publication of this Case Report
and any accompanying images.
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